Antineutrophil cytoplasm antibody-associated vasculitis: Recent developments

Kidney International

Volumn 84, Issue 2, 2013, Pages 244-249

  Furuta, Shunsuke ^a   Jayne, David R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

ANCA associated vasculitis; Classification; Granulomatosis with polyangiitis; Microscopic polyangiitis; Treatment

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; LEVAMISOLE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; METHOTREXATE; MOESIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMINOGEN; PREDNISOLONE; PROPYLTHIOURACIL; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; CARDIOVASCULAR RISK; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; NEUTROPHIL; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; TREATMENT OUTCOME;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; BIOPSY; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84881134380     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.24     Document Type: Short Survey

References (25)

1. Basu N, Watts R, Bajema I et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69: 1744-1750.
2. Jennette J, Falk R, Bacon P et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2012; 65: 1-11.
3. Mahr A, Katsahian S, Varet H et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2012 (e-pub ahead of print).
4. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367: 214-223.
5. Kain R, Tadema H, McKinney EF et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2012; 23: 556-566.
6. Roth AJ, Brown MC, Smith RN et al. Anti-LAMP-2 antibodies are not prevalent in patients with anti-neutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012; 23: 545-555.
7. Nagao T, Suzuki K, Utsunomiya K et al. Direct activation of glomerular endothelial cells by anti-moesin activity of anti-myeloperoxidase antibody. Nephrol Dial Transplant 2011; 26: 2752-2760.
8. Berden AE, Nolan SL, Morris HL et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCAassociated vasculitis. J Am Soc Nephrol 2010; 21: 2169-2179.
9. Nakazawa D, Tomaru U, Suzuki A et al. Abnormal conformation and impaired degradation of NETs induced by propylthiouracil: Implication of disordered NETs in MPO-ANCA-associated vasculitis. Arthritis Rheum 2012; 64: 3779-3787.
10. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628-1636.
11. Berden AE, Jones RB, Erasmus DD et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012; 23: 313-321.
12. Abdulahad WH, Lamprecht P, Kallenberg CG. T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther 2011; 13: 236.
13. Xing GQ, Chen M, Liu G et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009; 29: 282-291.
14. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
15. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220.
16. Walsh M, Merkel PA, Mahr A et al. Effects of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res 2010; 62: 1166-1173.
17. Walsh M, Catapano F, Szpirt W et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011; 57: 566-574.
18. Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012; 64: 3760-3769.
19. Faurschou M, Westman K, Rasmussen N et al. Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis. Arthritis Rheum 2012; 64: 3472-3477.
20. Harper L, Morgan MD, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955-960.
21. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488-494.
22. Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-548.
23. Suppiah R, Judge A, Batra R et al. A model to predict cardiovascular events in patients with newly diagnosed wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res 2011; 63: 588-596.
24. Heijl C, Harper L, Flossmann O et al. Incidence of malignancy in patients treated for anti-neutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group trials. Ann Rheum Dis 2011; 70: 1415-1421.
25. Guenno GL, Mahr A, Pagnoux C et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011; 63: 1435-1445.